=RHOM1)|X0I<$5_B&I'!<0A@OR
SYSTEM PROCESSING...
=RHOM1)|X0I<$5_B&I'!<0A@OR
SYSTEM PROCESSING...
Posted: 2025-04-24 04:41:01 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-24 04:43:11 UTC
Verified By
Rollup News
A great debate published in the European Heart Journal (EHJ) discusses whether plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease.
Plasma triglycerides (TG) as a biomarker for TRL.
The role of remnant cholesterol in atherosclerotic plaques.
The impact of TG-lowering treatments on cardiovascular disease risk.
Establishing a definitive causal link between plasma TG and CVD.
Assessing the robustness of TG-lowering for CVD risk reduction.
Understanding the complex mechanisms of TRL atherogenicity.